Rep. J. French Hill Sells Pfizer Inc. (NYSE:PFE) Shares

Representative J. French Hill (R-Arkansas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on January 23rd, the Representative disclosed that they had sold between $100,001 and $250,000 in Pfizer stock on December 31st. The trade occurred in the Representative’s “HILL 2012 TRUST” account.

Representative J. French Hill also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Kyndryl (NYSE:KD) on 12/31/2025.
• Sold $15,001 – $50,000 in shares of SFL (NYSE:SFL) on 12/31/2025.
• Sold $15,001 – $50,000 in shares of Solventum (NYSE:SOLV) on 12/31/2025.

Pfizer Trading Up 1.2%

Pfizer stock traded up $0.33 during trading hours on Friday, reaching $26.43. 51,562,944 shares of the company’s stock traded hands, compared to its average volume of 46,943,304. The firm has a market capitalization of $150.24 billion, a price-to-earnings ratio of 15.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The firm’s 50 day moving average is $25.52 and its 200-day moving average is $25.03.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Horizon Financial Services LLC grew its stake in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the last quarter. YANKCOM Partnership bought a new position in shares of Pfizer in the fourth quarter valued at $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the second quarter worth $29,000. Finally, Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the third quarter worth $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Cantor Fitzgerald lifted their price objective on Pfizer from $24.00 to $27.00 and gave the stock a “neutral” rating in a research note on Tuesday. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Bank of America cut their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.06.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post‑COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi‑year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology
• Positive Sentiment: Pfizer struck a non‑exclusive licensing agreement to access Novavax’s Matrix‑M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix‑M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full‑year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near‑term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near‑term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short‑term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

About Representative Hill

French Hill (Republican Party) is a member of the U.S. House, representing Arkansas’ 2nd Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Hill (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 2nd Congressional District. He declared candidacy for the 2026 election.

Hill is the founder and chairman of Delta Trust & Bank. He has served as senior policy advisor to President George H.W. Bush, Deputy Assistant Secretary of the U.S. Treasury and senior advisor to Governor Mike Huckabee.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.